Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.32 +12.1% TUNG 1.73 +2.4% LGO 1.00 −3.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.50 +1.1% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.32 +12.1% TUNG 1.73 +2.4% LGO 1.00 −3.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.50 +1.1% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
Other

COSCIENS Provides Strategic Update

By The Northwire Desk — AI Analysis Mar 05, 2026 · 17:10 CSCI · 2.11 COSCIENS BIOPHARMA INC
CSCI · Price

Executive Summary

  • COSCIENS Biopharma Inc. will cease all financing to its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, prompting a structured insolvency process for those entities.
  • The company expects to surrender its rights to the Macrilen® product and significantly reduce operating expenses as a result of the insolvency.
  • Management frames the decision as a positive step toward profitability while continuing to focus on the active‑ingredients business and exploring other growth opportunities.

Key Details

  • Decision: Cease funding German subsidiaries (Aeterna Zentaris GmbH & Zentaris IVF GmbH).
  • Outcome Expected: Initiation of a structured insolvency process for the subsidiaries in the near future.
  • Impact on Assets: Anticipated surrender of COSCIENS’ rights to Macrilen® (macimorelin) and reduction of ongoing operating expenses.
  • Background: Macrilen is FDA and EMA‑approved for adult growth‑hormone deficiency diagnosis but has operated at a loss; Phase 3 DETECT trial results and a Type C FDA meeting disappointed expectations for pediatric approval.
  • Strategic Review Considerations: Explored (i) alternative U.S. market expansion options, (ii) possible sale of the product or subsidiaries, (iii) additional licensing/partnership opportunities.
  • Recent Activity: Despite a newly announced distribution agreement with Wuzhou Drug International Trading Limited, the board concluded that ceasing financing was the best path forward.
  • Management Quote: Peter Puccetti, Interim CEO & Chairman, stated the decision “marks a significant and positive step towards the Company’s goal of achieving profitability.”
  • Future Focus: Continue to maximize profitability of the active‑ingredients business and evaluate other strategic opportunities.

Notable Quotes

“The Board did not make this decision lightly, but we firmly believe it marks a significant and positive step towards the Company’s goal of achieving profitability.” – Peter Puccetti, Interim CEO & Chairman of the Board

Read the original news release →

More from COSCIENS BIOPHARMA INC

Jun 18, 2026 · 08:30

SEC deregistration cleared, permanent CEO installed, but cash runway remains tight.

Management May 12, 2026 · 17:05

COSCIENS Posts Accounting Profit Amidst Cash Burn and Program Cuts

Earnings Apr 20, 2026 · 08:00

COSCIENS Biopharma Proposes Share Consolidation to Cut Reporting Costs and Exit U.S. Registry

Other Mar 25, 2026 · 17:05

COSCIENS Sheds German Subsidiaries and $11M Pension Liability as Cash Burn Outpaces Declining Revenue

Earnings Dec 01, 2025 · 17:05

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen(TM) in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

M&A / Property Nov 14, 2025 · 17:15

COSCIENS Biopharma Inc. Announces Leadership Change

Management